Nasal naloxone 'inferior' for reversing overdose
But given it still works, users should choose the option they're comfortable with, researchers say
15th November 2019
This story has been updated. Australian Doctor would like to clarify that the naloxone formulations used in the trial were prepared specifically for the trial and were not approved therapeutic products on the Australian market. The study did not use the branded nasal spray Nyxoid, which is PBS listed.
Nasal delivery of naloxone hydrochloride is inferior to intravenous injection in reversing opioid overdose, despite being the easier dispensing method, an Australian study suggests.
But researchers say while an
